The US House Financial Services Committee will consider the American Reserve Modernization Act (ARMA) of 2026 on September 16, which proposes creating a strategic Bitcoin reserve. The bill aims to hold Bitcoin for at least 20 years and use future sales to reduce national debt, formalizing government management of digital assets seized from criminal cases. Despite holding 328,000 BTC, the US faces competition from other countries accumulating Bitcoin as a digital asset. However, due to a tight Congressional calendar and low political momentum, the bill's chances of passing before 2027 remain below 10%.
The US Bitcoin reserve bill faces low odds in Congress, with a chance below 10%, as of Sep 16, 2026 03:28 WIB. For readers following cryptocurrency market activity, here is Pluang's market snapshot as of Sep 16, 2026 03:28 WIB: out of 50 major cryptocurrencies priced on Pluang, 4 rose and 45 fell today. Notable movers include FIL (Filecoin) down 15.30%, XRP (Ripple) down 13.89%, and BAL (Balancer) up 11.14%.
Pacira BioSciences was downgraded from Buy to Hold by Needham following Viatris's announcement to acquire the company for $36.50 per share, valuing it at about $1.65 billion. The deal is expected to close by late 2026 and will enhance Viatris's portf...
Equifax has introduced Mortgage Score Select, a new tool allowing mortgage lenders and brokers to choose which credit score to include on a mortgage credit file or to pull the file without a score. This innovation offers cost savings by enabling a se...
Nearly 2,000 mortgage lenders are using Equifax's VantageScore 4.0 credit scoring model, which incorporates alternative data like rental and utility payments, to improve borrower evaluation and expand credit access. Equifax has extended the $1 pricin...
Ashish Kumar, former AI lead for Tesla's humanoid robot Optimus, has founded Intelligent Machines, a startup focused on building task-specific industrial robots rather than humanoid ones. The company uses reinforcement learning to train robots for sp...
argenx SE (ARGX) shares fell over 10% on October 8, 2026, after the company stopped its Phase 3 UNITY trial of subcutaneous Vyvgart for Sjögren's disease due to futility. An independent committee found the study unlikely to meet its primary endpoint,...
